var data={"title":"Remifentanil: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Remifentanil: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6901?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">see &quot;Remifentanil: Drug information&quot;</a> and <a href=\"topic.htm?path=remifentanil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Remifentanil: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50847614\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada, in collaboration with manufacturers, will update the Canadian labelling of all prescription opioid products to include the following:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation for a daily opioid threshold dose for the management of chronic noncancer, nonpalliative pain (which aims to reduce risks of adverse events and overdoses associated with higher doses of opioids);</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation to limit the quantity of opioids prescribed for acute pain (which aims to reduce the duration of use and associated risks of developing dependence and substance use disorder); and</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Clarification of warnings, including those for special populations such as pregnant women and patients with a history of dependence or substance use disorder.</p></li></ul>\n        <p style=\"text-indent:0em;\">Health Canada has prioritized product tables for updating based on risk. The labelling updates for all prescription opioids are expected to be completed in January 2019.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65362a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49462182\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Addiction, abuse, and misuse:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Remifentanil exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient&rsquo;s risk prior to prescribing remifentanil.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217521\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ultiva</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217522\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Remifentanil Hydrochloride for Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2734185\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Analgesic, Narcotic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">General Anesthetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444952\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthesia, maintenance of anesthesia with nitrous oxide (70%):</b> Continuous IV infusion: 0.4 mcg/kg/minute (range: 0.4-1 mcg/kg/minute); supplemental bolus dose of 1 mcg/kg may be administered; smaller bolus dose may be required with potent inhalation agents, potent neuraxial anesthesia, significant comorbidities, significant fluid shifts, or without atropine pretreatment. Clearance in neonates is highly variable; dose should be carefully titrated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Analgesia/sedation in mechanically ventilated patients:</b> Limited data available, dosage not established: Continuous IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm infants: Initial: 0.075 mcg/kg/minute, titrate to effect; dosing based on a trial in 48 preterm infants requiring mechanical ventilation (GA: Mean: 28.5 weeks, range: 25-33 weeks; PNA: 1-17 days); in a large majority of the patients (73%), dose escalation from the initial dose was required within the first 6 hours of therapy; mean effective dose: 0.11 &plusmn; 0.05 mcg/kg/minute, maximum reported dose: 0.94 mcg/kg/minute. No cardiovascular or respiratory adverse effects were observed (Giannantonio, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term infants: Initial: 0.15 mcg/kg/minute, titrate to effect; dosing based on a randomized, double-blind, comparative study of neonates and young infants (n=23; GA: &ge;36 weeks; PNA: &lt;60 days) requiring mechanical ventilation who were given a combination of either midazolam/remifentanil (n=11) or midazolam/fentanyl (n=12); mean remifentanil effective dose: 0.23 mcg/kg/minute; maximum reported dose: 0.5 mcg/kg/minute; efficacy data and adverse effect profile were similar to fentanyl (Welzing, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endotracheal intubation, nonemergent:</b> Limited data available: IV: 1-3 mcg/kg/dose; may repeat dose in 2-3 minutes if needed (Choong, 2010; Kumar, 2010; Silva, 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2734196\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">see &quot;Remifentanil: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: <b>Note:</b> Continuous IV infusion: Dose should be based on ideal body weight (IBW) in obese patients (&gt;30% over IBW).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesia (postoperative); mechanically ventilated patient:</b> Limited data available: Children and Adolescents 3-16 years: Continuous IV infusion: 0.1 mcg/kg/minute with or without adjunctive medication, titrate to effect; dosing based on a randomized, double-blind comparative trial of remifentanil versus fentanyl in 22 postoperative orthopedic spinal surgery patients requiring mechanical ventilation (remifentanil group, n=11; age: Mean:13 years, range: 3-16 years); similar efficacy and adverse effect profile were reported with both treatment groups (Akinci, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesia/sedation in mechanically ventilated patients:</b> Limited data available: Infants &le;2 months: Continuous IV infusion: Initial: 0.15 mcg/kg/minute, titrate to effect; dosing based on a randomized, double-blind, comparative study of neonates and young infants (n=23; GA: &ge;36 weeks; PNA: &lt;60 days) requiring mechanical ventilation who were given a combination of either midazolam/remifentanil (n=11) or midazolam/fentanyl (n=12); mean remifentanil effective dose: 0.23 mcg/kg/minute; maximum reported dose: 0.5 mcg/kg/minute; efficacy data and adverse effect profile were similar to fentanyl (Welzing, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anesthesia, maintenance of anesthesia: </b> Continuous IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 1-2 months: Maintenance of anesthesia with nitrous oxide (70%): 0.4 mcg/kg/minute (range: 0.4-1 mcg/kg/minute); supplemental bolus dose of 1 mcg/kg may be administered, smaller bolus dose may be required with potent inhalation agents, potent neuraxial anesthesia, significant comorbidities, significant fluid shifts, or without atropine pretreatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, and Adolescents: Limited data available: Maintenance of anesthesia with halothane, sevoflurane, or isoflurane: 0.25 mcg/kg/minute (range: 0.05-1.3 mcg/kg/minute); supplemental bolus dose of 1 mcg/kg may be administered every 2-5 minutes. Consider increasing concomitant anesthetics with infusion rate &gt;1 mcg/kg/minute. Infusion rate can be titrated upward in increments up to 50% or titrated downward in decrements of 25% to 50%. May titrate every 2-5 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anesthesia, total intravenous (TIVA); with or without propofol induction: </b> Limited data available: IV: Loading dose (may omit if propofol induction used): 0.5 mcg/kg/minute for 3 minutes (total dose: 1.5 mcg/kg) or 1 mcg/kg over 1 minute; followed by an initial maintenance dose: 0.05-0.1 mcg/kg/minute; titrate in 0.05 mcg/kg/minute increments every 3 minutes to effect; usual effective range: 0.2-0.5 mcg/kg/minute; has been used in combination with propofol (bolus and/or infusion) (Malherbe, 2010a; Malherbe, 2010b; Mani, 2010; Shen, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endotracheal intubation for elective procedures:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Usual range: 1-3 mcg/kg/dose, doses as high as 4 mcg/kg have been used. Dosing based on multiple trials in patients undergoing elective procedures requiring intubation who were not receiving neuromuscular blockers and remifentanil administered in combination with other induction agents such as propofol, ketamine, or sevoflurane. (Begec, 2009; Blair, 2004; Hume-Smith, 2010; Klemola, 2000; Morgan, 2007; Park, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal (using parenteral 100 mcg/mL formulation): Children &le;7 years: 4 mcg/kg/dose; administer half of the total dose in each nostril; wait 2-3 minutes before attempting intubation. Dosing based on a double-blind, randomized, controlled trial (n=188), remifentanil was administered after sevoflurane induction and overall, was found more effective than saline placebo at both endpoints of 2 minutes and 3 minutes postdose. Results also showed that within the remifentanil treatment groups, good or excellent intubation conditions were reported more often at 3 minutes postdose than at 2 minutes (91.7% vs 68.2%) (Verghese, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Procedural sedation:</b> Limited data available, dosage not established: IV: 0.5 mcg/kg with propofol has been used to induce analgesia and adjunct sedation prior to esophagogastroduodenoscopy (n=22; age range: 2-12 years) and short hemato-oncologic invasive procedures (n=30, age range: 2-18 years) (Hirsh, 2010; Ince, 2013). A higher dose of 3 mcg/kg was used in already sedated (sevoflurane) infants and young children who required apnea for CT or MRI imaging (n=12, age range: 6-16 months) (Joshi, 2009). In a dose-finding trial, continuous IV infusion of remifentanil at 0.2 mcg/kg/minute has been shown more effective than a lower 0.1 mcg/kg/minute in 60 children 2-12 years undergoing diagnostic cardiac catheterization; pretreatment with oral midazolam and local groin anesthetic also utilized (Kaynar, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Induction of anesthesia:</b> 0.5-1 mcg/kg/minute; if endotracheal intubation is to occur in &lt;8 minutes, an initial dose of 1 mcg/kg may be given over 30-60 seconds; in coronary bypass surgery: 1 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Maintenance of anesthesia: Note:</b> Supplemental bolus dose of 1 mcg/kg may be administered every 2-5 minutes. Consider increasing concomitant anesthetics with infusion rate &gt;1 mcg/kg/minute. Infusion rate can be titrated upward in increments of 25% to 100% or downward in decrements of 25% to 50%. May titrate every 2-5 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">With nitrous oxide (66%): 0.4 mcg/kg/minute (range: 0.1-2 mcg/kg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">With isoflurane: 0.25 mcg/kg/minute (range: 0.05-2 mcg/kg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">With propofol: 0.25 mcg/kg/minute (range: 0.05-2 mcg/kg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Coronary bypass surgery: 1 mcg/kg/minute (range: 0.125-4 mcg/kg/minute); supplemental dose: 0.5-1 mcg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Continuation as an analgesic in immediate postoperative period:</b> 0.1 mcg/kg/minute (range: 0.025-0.2 mcg/kg/minute). Infusion rate may be adjusted every 5 minutes in increments of 0.025 mcg/kg/minute. Bolus doses are not recommended. Infusion rates &gt;0.2 mcg/kg/minute are associated with respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Coronary bypass surgery, continuation as an analgesic into the ICU: 1 mcg/kg/minute (range: 0.05-1 mcg/kg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesic component of monitored anesthesia care: Note:</b> Supplemental oxygen is recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Single IV dose given 90 seconds prior to local anesthetic:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Remifentanil alone: 1 mcg/kg over 30-60 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">With midazolam: 0.5 mcg/kg over 30-60 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion beginning 5 minutes prior to local anesthetic:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Remifentanil alone: 0.1 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">With midazolam: 0.05 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion given after local anesthetic:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Remifentanil alone: 0.05 mcg/kg/minute (range: 0.025-0.2 mcg/kg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">With midazolam: 0.025 mcg/kg/minute (range: 0.025-0.2 mcg/kg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Following local or anesthetic block, infusion rate should be decreased to 0.05 mcg/kg/minute; rate adjustments of 0.025 mcg/kg/minute may be done at 5-minute intervals</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Removed by hemodialysis (30%). There are no dosage adjustments provided in the manufacturer's labeling; however, remifentanil pharmacokinetics are unchanged in patients with end stage renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, remifentanil pharmacokinetics are unchanged in patients with severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217497\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mcg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ultiva: 1 mg (1 ea); 2 mg (1 ea); 5 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg (1 ea); 2 mg (1 ea); 5 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217482\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217553\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2734197\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: An infusion pump should be used to administer continuous infusions. During the maintenance of general anesthesia, IV boluses &le;1 mcg/kg may be administered over 30 to 60 seconds; for doses &gt;1 mcg/kg, administer over &gt;60 seconds (to reduce the potential to develop skeletal muscle and chest wall rigidity). Injections should be given into IV tubing close to the venous cannula; tubing should be cleared after treatment to prevent residual effects when other fluids are administered through the same IV line.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217515\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Stable for 24 hours at room temperature after reconstitution and further dilution in SWFI, D5LR, D5NS, D5W, <sup>1</sup>/<sub>2</sub>NS, or NS to concentrations of 20 to 250 mcg/mL (4 hours if diluted with LR).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2734186\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Analgesic for use during the induction of general anesthesia (FDA approved in adults); maintenance of general anesthesia (FDA approved in ages 0-2 months, 1-12 years, and adults); continued analgesia into the immediate postoperative period (FDA approved in adults); as the analgesic component of monitored anesthesia (FDA approved in adults); has also been used as adjunct for analgesia during endotracheal intubation, for total intravenous anesthesia (TIVA), and for continuous analgesia/sedation in critically ill mechanically ventilated patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217560\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Remifentanil may be confused with alfentanil</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217557\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia (dose-dependent), flushing, flushing sensation, hypertension (dose-dependent), hypotension, shivering, tachycardia (dose-dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, dizziness, chills, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Muscle rigidity (includes chest wall rigidity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, hypoxia, respiratory depression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, postoperative pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal distress, amnesia, anaphylaxis, anxiety, awareness under anesthesia without pain, bronchitis, bronchospasm, cardiac arrhythmia, chest pain, confusion, constipation, cough, diarrhea, disorientation, disruption of body temperature regulation, dysphagia, dysphoria, dyspnea, dysuria, ECG changes, electrolyte disturbance, erythema, gastroesophageal reflux disease, hallucination, heart block, heartburn, hepatic insufficiency, hiccups, hyperglycemia, increased creatine phosphokinase, intestinal obstruction, involuntary body movements, laryngospasm, leukocytosis, lymphocytopenia, nasal congestion, nightmares, nystagmus, oliguria, paresthesia, pharyngitis, pleural effusion, prolonged emergence from anesthesia, pulmonary edema, rales, rapid awakening from anesthesia, rhinorrhea, rhonchi, seizure, skin rash, sleep disorder, stridor, syncope, thrombocytopenia, tremor, twitching, urinary incontinence, urinary retention, urticaria, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217504\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis) to remifentanil or any component of the formulation; intrathecal or epidural administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for opioids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217486\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intraoperative awareness:  Intraoperative awareness has been reported when used with propofol infusion rates of &le;75 mcg/kg/minute in patients &lt;55 years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: Serious, life-threatening, or fatal respiratory depression, even when used as recommended may occur. Monitor closely for respiratory depression, especially during initiation or dose escalation. Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with concomitant use of remifentanil and serotonergic agents (eg, SSRIs, SNRIs, triptans, TCAs, 5-HT<sub>3</sub> receptor antagonists, mirtazapine, trazodone, tramadol) and agents that impair metabolism of serotonin (eg, MAO inhibitors). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue remifentanil if serotonin syndrome is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis; opioids may cause constriction of sphincter of Oddi.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia: Use with caution when administering to patients with bradycardia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delirium tremens: Use with caution in patients with delirium tremens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in patients who are morbidly obese.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Use with caution in patients with toxic psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with a history of seizure disorders; may increase risk or exacerbate preexisting seizure disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in hypotension, profound sedation, respiratory depression, coma, and death. Alcohol should be avoided for 24 hours after surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information<i>.</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion:  <b>[US Boxed Warning]: Remifentanil exposes users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient&rsquo;s risk prior to prescribing remifentanil.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Inadequate clearing of IV tubing following administration has been associated with  muscle rigidity, respiratory depression, and apnea when another fluid is administered through the same line. Do not administer into the same IV tubing with blood due to potential inactivation by nonspecific esterases in blood products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Interruption of an infusion will result in offset of effect within 5 to 10 minutes; the discontinuation of an infusion should be preceded by the establishment of adequate postoperative analgesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; General anesthesia use: Not recommended as the sole agent for induction of anesthesia, because the loss of consciousness cannot be assured.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rapid infusion: Rapid IV infusion (single dose &gt;1 mcg/kg over 30 to 60 seconds and infusion rates &gt;0.1 mcg/kg/minute) should only be used during maintenance of general anesthesia; rapid infusion may result in skeletal muscle and chest wall rigidity. Chest wall rigidity may resolve by decreasing the infusion rate, discontinuing the infusion, or by administering a neuromuscular blocking agent.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained individuals: Remifentanil should only be administered by health care providers specifically trained in the use of anesthetic agents. Should not be used in diagnostic or therapeutic procedures outside the monitored anesthesia setting; resuscitative and intubation equipment should be readily available.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299990\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217491\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12998&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May enhance the analgesic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Opioids (Anilidopiperidine) may enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): Opioids (Anilidopiperidine) may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Opioids (Anilidopiperidine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Opioid Analgesics. Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Opioid Analgesics may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: May diminish the therapeutic effect of Opioid Analgesics. Management: Avoid the concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics. If combined, larger doses of opioid analgesics will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids.  See full drug interaction monograph for detailed recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Analgesics. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Opioid Analgesics may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Opioid Analgesics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: May enhance the bradycardic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217507\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events  have not been observed in animal reproduction studies. Remifentanil has been shown to cross the placenta; fetal and maternal concentrations may be similar. Use during labor and delivery is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2734198\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory and cardiovascular status, blood pressure, heart rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217485\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds with stereospecific mu-opioid receptors at many sites within the CNS, increases pain threshold, alters pain reception, inhibits ascending pain pathways</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217503\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In pediatric patients (neonates through adolescents), pharmacokinetic data showed variable age-related changes with distribution (ie, highest V<sub>d</sub> associated with lowest age) and clearance (ie, fastest clearance in the youngest patients); however, no age-related changes with half-life (Ross 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IV: 1 to 3 minutes; Peak effect: 3 to 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 3 to 10 minutes (Scott 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (Ross 2001): V<sub>dss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates &le;2 months: 453 &plusmn; 145 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &gt;2 months to &lt;2 years: 308 &plusmn; 89 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 6 years: 240 mL/kg &plusmn; 131 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 7 to 12 years: 249 mL/kg &plusmn; 91 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents 13 to &lt;16 years: 223 &plusmn; 31 mL/kg</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Adolescents 16 to 18 years: 243 &plusmn; 109 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: V<sub>d</sub>: Initial: 100 mL/kg; V<sub>dss</sub>: 350 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~70% (primarily alpha-1 acid glycoprotein)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Rapid via blood and tissue esterases; not metabolized by plasma cholinesterase (pseudocholinesterase) and is not appreciably metabolized by the liver</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination (dose dependent):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (Ross 2001): Effective:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates &le;2 months: 5.4 minutes (range: 3 to 8 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &gt;2 months to &lt;2 years: 3.4 minutes (range: 2 to 6 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 6 years: 3.6 minutes (range: 1 to 6 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 7 to 12 years: 5.3 minutes (range: 3 to 7 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: 13 to &lt;16 years: 3.7 minutes (range: 2 to 5 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents 16 to 18 years: 5.7 minutes (range: 5 to 6 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Terminal: 10 to 20 minutes; Effective: 3 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Intranasal: Children &le;7 years: ~3.5 minutes (Verghese 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (Ross 2001):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates &le;2 months of age: 90.5 &plusmn; 36.8 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &gt;2 months to &lt;2 years: 92.1 &plusmn; 25.8 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 6 years: 76.0 &plusmn; 22.4 mL/minute/kg</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Children 7 to 12 years: 59.7 &plusmn; 22.5 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents 13 to &lt;16 years: 57.2 &plusmn; 21.2 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents 16 to 18 years: 46.5 &plusmn; 2.1 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~40 mL/minute/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323781\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Remifentanil HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $70.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (1): $141.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $301.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ultiva Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $73.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (1): $147.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $312.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Remifentanil HCl-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100MCG/2ML 0.9% (2 mL): $14.11</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217508\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Remiva (KR);</li>\n      <li>Restinil (PY, UY);</li>\n      <li>Rui Jei (CN);</li>\n      <li>Sagal (PY);</li>\n      <li>Ulremif (BG);</li>\n      <li>Ultiva (AE, AR, AT, AU, BB, BE, BH, BM, BR, BS, BZ, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, IE, IL, IQ, IR, IT, JM, JO, JP, KR, KW, LB, LK, LT, LU, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PL, PT, QA, RO, SA, SE, SG, SI, SK, SR, SV, SY, TR, TT, VE, YE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abu-Kishk I, Hod-Feins R, Anekstein Y, et al. Remifentanil use in pediatric scoliosis surgery &ndash; an effective alternative to morphine (a retrospective study). <i>Yonsei Med J</i>. 2012;53(5): 1014-1021.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/22869487/pubmed\" target=\"_blank\" id=\"22869487\">22869487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Akinci SB, Kanbak M, Guler A, et al. Remifentanil versus fentanyl for short-term analgesia-based sedation in mechanically ventilated postoperative children. <i>Pediatric Anesthesia</i>. 2005;15:870-878.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/16176316/pubmed\" target=\"_blank\" id=\"16176316\">16176316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. <i>Crit Care Med</i>. 2013;41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Begec Z, Demirbilek S, Ozturk E, et al. Remifentanil and propofol for tracheal intubation without muscle relaxant in children: the effects of ketamine. <i>Eur J Anaesthesiol</i>. 2009;26:213-217.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/19244696/pubmed\" target=\"_blank\" id=\"19244696\">19244696</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blair JM, Hill DA, Wilson CM, et al. Assessment of tracheal intubation in children after induction with propofol and different doses of remifentanil. <i>Anesthesia</i>. 2004;59:27-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/14687095/pubmed\" target=\"_blank\" id=\"14687095\">14687095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choong L, AlFaleh K, Doucette J, et al. Remifentanil for endotracheal intubation in neonates: a randomized controlled trial. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2010;95,F80-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/20231228/pubmed\" target=\"_blank\" id=\"20231228\">20231228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fotopoulou G, Theocharis S, Vasileiou I, et al. Management of the airway without the use of neuromuscular blocking agents: the use of remifentanil.<i> Fundamental and Clinical Pharmacology</i>. 2012;72-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/21771056/pubmed\" target=\"_blank\" id=\"21771056\">21771056</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giannantonio C, Sammartino M, Valente E, et al. Remifentanil analgosedation in preterm newborns during mechanical ventilation. <i>Acta Paediatrica</i>. 2009;98(7):1111-1115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/19638014/pubmed\" target=\"_blank\" id=\"19638014\">19638014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsh I, Lerner A, Schnaider I, et al. Remifentanil versus fentanyl for esophagogastroduodenoscapy in children. <i>JPGN</i>. 2010;51:618-621.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/20808251/pubmed\" target=\"_blank\" id=\"20808251\">20808251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hume-Smith H, McCormack J, Montgomery C, et al. The effect of age on the dose of remifentanil for tracheal intubation in infants and children. <i>Pediatric Anesthesia</i>. 2010;20:19-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/19968808/pubmed\" target=\"_blank\" id=\"19968808\">19968808</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ince IE, Iyilikci L, Yilmaz S, et al.. Sedation for short hemato-oncologic invasive procedures in children: comparison of propofol-remifentanil and propofol-fentanyl. <i>J Pediatr Hematol Oncol</i>. 2013;35:112-117.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/23412587/pubmed\" target=\"_blank\" id=\"23412587\">23412587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joshi G and Tobias J. Remifentanil to facilitate high-resolution computed tomography imagine of the chest or magnetic resonance imaging in infants. <i>Southern Medical Journal</i>. 2009;102(11):1121-1124.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/19864975/pubmed\" target=\"_blank\" id=\"19864975\">19864975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaynar A, Kelsaka E, Karakaya D, et al. Effects of different doses of remifentanil infusion on hemodynamics and recovery in children undergoing pediatric diagnostic cardiac catheterization. <i>Journal of Cardiothoracic and Vascular Anesthesia</i>. 2011;25(4):660-664.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/21109462/pubmed\" target=\"_blank\" id=\"21109462\">21109462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klemola U, Hiller A. Tracheal intubation after induction of anesthesia in children with propofol &ndash; remifentanil or propofol-rocuronium. <i>Can J Anesth</i>. 2000;47(9):854-859.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/10989854/pubmed\" target=\"_blank\" id=\"10989854\">10989854</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar P, Denson SE, Mancuso TJ, et al. Premedication for nonemergency endotracheal intubation in the neonate. <i>Pediatrics</i>. 2010;125(3):608-615.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/20176672/pubmed\" target=\"_blank\" id=\"20176672\">20176672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malherbe S, Ansermino JM. Total intravenous anesthesia and spontaneous ventilation for foreign body removal in children: how much drug? <i>Anesth Analg</i>. 2010a;111(6):1566.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/21106979/pubmed\" target=\"_blank\" id=\"21106979\">21106979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malherbe S, Whyte S, Singh P, et al. Total intravenous anesthesia and spontaneous respiration for airway endoscopy in children &ndash; a prospective evaluation. <i>Pediatric Anesthesia</i>. 2010b;20:434-438.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mani V, Morton N. Overview of total intravenous anesthesia in children. <i>Pediatric Anesthesia</i>. 2010;20:211-222.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/19694975/pubmed\" target=\"_blank\" id=\"19694975\">19694975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, Academy Of Breastfeeding Medicine. ABM cinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. <i>Breastfeed Med</i>. 2012;7(6):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan JM, Barker I, Peacock JE, et al. A comparison of intubating conditions in children following induction of anaesthesia with propofol and suxamethonium or propofol and remifentanil.<i> Anesthesia</i>. 2007;62:135-139.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/17223805/pubmed\" target=\"_blank\" id=\"17223805\">17223805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park KS, Park SY, Kim JW, et al. Effect of remifentanil on tracheal intubation conditions and haemodynamics in children anaesthetized with sevoflurane and nitrous oxide.  <i>Anaesth Intensive Care</i>. 2009;37:577-583.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/19681414/pubmed\" target=\"_blank\" id=\"19681414\">19681414</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross AK, Davis PJ, Dear Gd GL, et al. Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures. <i>Anesth Analg</i>. 2001;93:1393-1401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/11726413/pubmed\" target=\"_blank\" id=\"11726413\">11726413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott LJ, Perry CM. Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. <i>Drugs</i>. 2005;65(13):1793-1823.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/16114980/pubmed\" target=\"_blank\" id=\"16114980\">16114980</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shen X, Hu C, Ye M, et al. Profol-remifentanil intravenous anesthesia and spontaneous ventilation for airway foreigh body removal in children with preoperative respiratory impairment. <i>Pediatric Anesthesia</i>. 2012;22:1166-1170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/22694274/pubmed\" target=\"_blank\" id=\"22694274\">22694274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silva YPE, Gomez RS, Marcatto JDO, et al.. Early awakening and extubation with remifentanil in ventilated premature neonates. <i>Pediatric Anesthesia</i>. 2008;18:176-183.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/18184251/pubmed\" target=\"_blank\" id=\"18184251\">18184251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ultiva (remifentanil hydrochloride) [prescribing information]. Rockford, IL; Mylan: December 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/18184251/pubmed\" target=\"_blank\" id=\"18184251\">18184251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verghese ST, Hannallah RS, Brennan M, et al. The effect of intranasal administration of remifentanil on intubating conditions and airway response after sevoflurane induction of anesthesia in children. <i>Anesth Analf</i>. 2008;107:1176-1181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/18806024/pubmed\" target=\"_blank\" id=\"18806024\">18806024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Welzing L, Oberthuer A, Junghaenel S, et al. Remifentanil/midazolam versus fentanyl/midazolam for analgesia and sedation of mechanically ventilated neonates and young infants: a randomized controlled trial.<i> Intensive Care Med</i>. 2012;38:1017-1024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/remifentanil-pediatric-drug-information/abstract-text/22456770/pubmed\" target=\"_blank\" id=\"22456770\">22456770</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12998 Version 137.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50847614\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F49462182\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F217521\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F217522\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F2734185\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444952\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F2734196\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F217497\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F217482\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F217553\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2734197\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F217515\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2734186\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F217560\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F217557\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F217504\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F217486\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299990\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F217491\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F217507\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2734198\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F217485\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F217503\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323781\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F217508\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12998|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=remifentanil-drug-information\" class=\"drug drug_general\">Remifentanil: Drug information</a></li><li><a href=\"topic.htm?path=remifentanil-patient-drug-information\" class=\"drug drug_patient\">Remifentanil: Patient drug information</a></li></ul></div></div>","javascript":null}